Cervical cancer drug raises survival rate by 30% compared to chemotherapy: ‘Game-changer’
Fox News
The prescription medicine TIVDAK is showing positive results for treating cervical cancer after a phase 3 trial. Drs. Brian Slomovitz and Kathleen Moore reveal its efficacy and potential.
In phase 3 global trials, TIVDAK (tisotumab vedotin) was linked to a 30% overall reduction in the risk of death compared to chemotherapy. "In the past, we just did not have active medications and our patients really were left with ineffective therapies, and they just died." "They’re feeling better because their disease is shrinking." Angelica Stabile is a lifestyle writer for Fox News Digital.
TIVDAK also demonstrated a 33% decrease in the risk of worsening disease or death.
Clonazepam, popular anxiety-reducing drug, recalled nationwide for ‘possibly life-threatening’ error
The anxiety-reducing drug, Clonazepam, has been recalled after a potentially "life-threatening" label mix-up, the FDA said in the recall.